HIV-1 p24 anticorps

N° du produit ABIN7849766

Cet anticorps anti-HIV-1 p24 Monoclonal Souris (Clone E12) (ABIN7849766) détecte spécifiquement HIV-1 p24 dans ELISA. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour HIV-1 p24 anticorps (ABIN7849766)

Antigène: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HIV-1 p24 est non-conjugé

Application: ELISA

Clone: E12

Détail du produit anti-HIV-1 p24 anticorps

Fonction: Monoclonal Anti- HIV-1 p24 (Detection Ab)

Attributs du produit: This antibody may be used as in antibody pair experiments such as ELISA.

Purification: Protein A or G purified

Pureté: >95 % by HPLC & SDS-PAGE

Immunogène: Recombinant human HIV-1 p24 Protein (Expression system with E.Coli).

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 0.9 % NaCl without preservative.

Agent conservateur: Without preservative

Conseil sur la manipulation: Avoid repeated freeze and thaw cycles.

Stock: -20 °C

Stockage commentaire: Aliquot and store at -20°C for long term (at least for one year). Avoid repeated freeze and thaw cycles.

Date de péremption: 12 months

Détails sur HIV-1 p24

Antigène: HIV-1 p24 (Human Immunodeficiency Virus 1 Capsid (HIV-1 p24))

Autre désignation: HIV-1 p24

Classe de substances: Viral Protein

Sujet: Acquired immune deficiency syndrome (HIV/AIDS) has been a major global health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in intracellular plasma membrane-connected structures termed virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. HIV-1 infection of macrophages leads to the sequestration of newly formed viruses in virus-containing compartments (VCCs), where virions remain infectious and hidden from immune surveillance. The transmembrane domain of Vpu and two motifs of the Vpu cytoplasmic domain are required for these functions. These motifs were notably involved in the control of the volume of VCCs by Vpu but were dispensable for the prevention of the specific accumulation of BST2 in these structures.